AVSOLA
infliximab-axxq
- Strength
- 100 mg/10mL
- Form
- Injection, Powder, Lyophilized, For Solution
- Class
- Tumor Necrosis Factor Blocker
Amgen, Inc
INFLIXIMAB
Listed by Janssen Biotech, Inc.
- Strength
- 100 mg/10mL
- Form
- Injection, Powder, Lyophilized, For Solution
- Route
- Intravenous
- Class
- Tumor Necrosis Factor Blocker
What it contains
- Infliximab 100 mg/10mL
FDA record
| Dosage form | Injection, Powder, Lyophilized, For Solution |
|---|---|
| Route | Intravenous |
| Drug class | Tumor Necrosis Factor Blocker |
| Approval route | BLA — biologic licence |
| NDC code | 57894-160 |
| FDA application | BLA103772 |
| RxNorm concept | 310994 |
| Package sizes listed | 1 |
| Marketed since | October 2021 |
Other products containing Infliximab
See allSame active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
INFLECTRA
infliximab-dyyb
- Strength
- 100 mg/10mL
- Form
- Injection, Powder, Lyophilized, For Solution
- Class
- Tumor Necrosis Factor Blocker
Pfizer Laboratories Div Pfizer Inc
REMICADE
INFLIXIMAB
- Strength
- 100 mg/10mL
- Form
- Injection, Powder, Lyophilized, For Solution
- Class
- Tumor Necrosis Factor Blocker
Janssen Biotech, Inc.
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.